GSK Tykerb Priced At Discount To Herceptin In Metastatic Breast Cancer

GlaxoSmithKline is pricing its breast cancer therapy Tykerb at a slight discount to Genentech's Herceptin (trastuzumab) in the metastatic breast cancer setting

More from Archive

More from Pink Sheet